PTC THERAPEUTICS INC's ticker is PTCT and the CUSIP is 69366J200. A total of 208 filers reported holding PTC THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $189,709,255 | -54.5% | 8,465,384 | -17.4% | 0.02% | -54.3% |
Q2 2023 | $416,994,553 | -55.1% | 10,253,124 | -46.5% | 0.04% | -16.7% |
Q1 2023 | $928,417,314 | +125.6% | 19,166,336 | +77.8% | 0.04% | +2.4% |
Q4 2022 | $411,560,620 | -23.6% | 10,782,306 | +0.5% | 0.04% | -26.8% |
Q3 2022 | $538,704,000 | +25.7% | 10,731,144 | +0.3% | 0.06% | +30.2% |
Q2 2022 | $428,675,000 | +7.1% | 10,700,837 | -0.2% | 0.04% | +34.4% |
Q1 2022 | $400,230,000 | -5.2% | 10,727,145 | +1.2% | 0.03% | +3.2% |
Q4 2021 | $422,384,000 | +7.2% | 10,604,685 | +0.1% | 0.03% | 0.0% |
Q3 2021 | $394,082,000 | -11.8% | 10,590,731 | +0.2% | 0.03% | -11.4% |
Q2 2021 | $446,724,000 | -10.6% | 10,568,386 | +0.2% | 0.04% | -18.6% |
Q1 2021 | $499,464,000 | -19.9% | 10,548,348 | +3.3% | 0.04% | -21.8% |
Q4 2020 | $623,351,000 | +31.6% | 10,213,855 | +0.8% | 0.06% | +14.6% |
Q3 2020 | $473,764,000 | +39.5% | 10,133,976 | +51.4% | 0.05% | +29.7% |
Q2 2020 | $339,691,000 | +56.1% | 6,694,744 | +37.2% | 0.04% | +23.3% |
Q1 2020 | $217,618,000 | +87.0% | 4,878,225 | +101.3% | 0.03% | +130.8% |
Q4 2019 | $116,370,000 | +40.3% | 2,422,842 | -1.2% | 0.01% | +30.0% |
Q3 2019 | $82,946,000 | -22.4% | 2,452,582 | +3.3% | 0.01% | -16.7% |
Q2 2019 | $106,850,000 | +16.5% | 2,374,442 | -2.6% | 0.01% | +9.1% |
Q1 2019 | $91,719,000 | -4.6% | 2,436,735 | -13.1% | 0.01% | -15.4% |
Q4 2018 | $96,182,000 | -26.0% | 2,802,517 | +1.3% | 0.01% | -13.3% |
Q3 2018 | $129,992,000 | +195.7% | 2,765,788 | +112.2% | 0.02% | +200.0% |
Q2 2018 | $43,959,000 | +45.7% | 1,303,254 | +16.8% | 0.01% | +25.0% |
Q1 2018 | $30,181,000 | +56.2% | 1,115,354 | -3.7% | 0.00% | +100.0% |
Q4 2017 | $19,318,000 | -16.6% | 1,158,154 | 0.0% | 0.00% | -33.3% |
Q3 2017 | $23,175,000 | +79.6% | 1,158,154 | +64.5% | 0.00% | +50.0% |
Q2 2017 | $12,904,000 | +93.9% | 703,973 | +4.1% | 0.00% | +100.0% |
Q1 2017 | $6,656,000 | -16.7% | 676,473 | -7.6% | 0.00% | 0.0% |
Q4 2016 | $7,987,000 | +127.6% | 732,044 | +192.2% | 0.00% | – |
Q3 2016 | $3,509,000 | -56.0% | 250,488 | -78.0% | 0.00% | -100.0% |
Q2 2016 | $7,976,000 | +9.0% | 1,136,211 | -0.0% | 0.00% | 0.0% |
Q1 2016 | $7,319,000 | -88.3% | 1,136,436 | -41.1% | 0.00% | -87.5% |
Q4 2015 | $62,533,000 | +61.8% | 1,930,027 | +33.3% | 0.01% | +33.3% |
Q3 2015 | $38,657,000 | -70.0% | 1,447,813 | -45.8% | 0.01% | -62.5% |
Q2 2015 | $128,679,000 | -58.2% | 2,673,563 | -47.1% | 0.02% | -59.0% |
Q1 2015 | $307,495,000 | +17.8% | 5,053,336 | +0.3% | 0.04% | +14.7% |
Q4 2014 | $260,941,000 | +32.9% | 5,040,381 | +13.0% | 0.03% | +25.9% |
Q3 2014 | $196,301,000 | +66.5% | 4,460,377 | -1.1% | 0.03% | +68.8% |
Q2 2014 | $117,922,000 | -0.0% | 4,511,167 | -0.0% | 0.02% | 0.0% |
Q1 2014 | $117,931,000 | +234.5% | 4,511,515 | +117.2% | 0.02% | +220.0% |
Q4 2013 | $35,251,000 | +8.4% | 2,077,218 | +37.1% | 0.01% | 0.0% |
Q3 2013 | $32,512,000 | – | 1,515,018 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,750,000 | $84,053,000 | 7.32% |
RTW INVESTMENTS, LP | 3,832,480 | $184,074,000 | 6.94% |
Burrage Capital Management LLC | 195,725 | $9,401,000 | 6.30% |
Asymmetry Capital Management, L.P. | 55,408 | $2,661,000 | 4.77% |
SECTORAL ASSET MANAGEMENT INC | 328,738 | $15,789,000 | 2.36% |
ARMISTICE CAPITAL, LLC | 758,000 | $36,407,000 | 2.10% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 114,000 | $5,470,000 | 1.97% |
Opaleye Management Inc. | 191,000 | $9,174,000 | 1.80% |
Sofinnova Investments, Inc. | 517,092 | $24,836,000 | 1.79% |
Chubb Ltd | 8,180 | $393,000 | 1.68% |